Longboard Pharmaceuticals

2024 - 10 - 14

Lundbeck kaster sig ud i bioteksfremtiden med 2,6 milliarder dollars!

Bexicaserin - Epilepsi - Farmaceutiske opkøb - Kliniske forsøg - Longboard Pharmaceuticals - Lundbeck - Neuro-lægemidler

Hold fast i hat og briller - Lundbeck køber Longboard Pharmaceuticals for 2,6 milliarder dollars. Er det fremtiden for epilepsimedicin?

Den danske medicinalvirksomhed H. Lundbeck A/S har netop indgået en historisk aftale om at købe det amerikanske bioteksfirma Longboard Pharmaceuticals for svimlende 2,6 milliarder dollars. Dette er den største handel, Lundbeck nogensinde har foretaget, og den viser virksomhedens ambition om at styrke sin position inden for behandling af hjernesygdomme. Longboard Pharmaceuticals, der er baseret i Californien, er kendt for at udvikle innovative og transformative behandlinger specifikt rettet mod neurologiske sygdomme, inklusive epilepsi.

Lundbeck vil betale 60,00 dollars pr. aktie i kontant for Longboard og vil finansiere handelen gennem nuværende kontante ressourcer samt bankfinansiering. Handelsaftalen har sendt aktierne i Longboard Pharmaceuticals op på rekordhøje niveauer, hvilket glæder investorerne og dels gør det tydeligt, at der er stor tillid til fremtidige produkter fra virksomheden. Lundbeck koncentrerer sig om at integrere Longboards lovende behandlinger, herunder deres førende aktiv, bexicaserin, som er i den afsluttende udviklingsfase for behandling af svære epilepsiformer som Dravet syndrom og Lennox-Gastaut syndrom.

Med denne strategiske erhvervelse ønsker Lundbeck at udvide sit produktudvalg og styrke sin forskningskapacitet inden for neurologi. Bexicaserin, en 5-HT2C receptor agonist, har vist lovende resultater i kliniske studier og kan være en game changer i behandlingen af anfald relateret til epilepsi. Lundbecks beslutning om at investere i Longboard indikerer en klar satsning på at tackle nogle af de mest udfordrende hjerne- og nervesygdomme, hvilket kunne have stor betydning for patienterne.

Det er ikke kun Lundbeck, der ser potentiale i denne aftale. Biotekssektoren generelt har set en stigende interesse og aktivitet, især når det kommer til medicin mod neurologiske lidelser. Ifølge eksperter kræver vi en ny tilgang til behandling af hjernesygdomme, og Lundbecks investering kan være afgørende for at udvikle mere effektive medicinske løsninger. Vidste du, at ca. 50 millioner mennesker i verden lider af epilepsi? Det gør denne erhvervelse endnu mere relevant for mange, der håber på bedre behandlingsmuligheder. Udover det, så er Lundbeck kendt for sin stærke arv indenfor udvikling af medicin, og denne aftale kunne skubbe grænserne for, hvad man troede var muligt indenfor neurologisk behandling.

Post cover
Image courtesy of "Reuters"

Denmark's Lundbeck bets on epilepsy drug with $2.6 bln Longboard ... (Reuters)

H Lundbeck A/S has agreed to buy U.S.-based Longboard Pharmaceuticals for $2.6 billion, marking the biggest deal ever by the Danish drugmaker as it seeks to ...

Post cover
Image courtesy of "Yahoo Finance"

Why Is Epilepsy Focused Longboard Pharmaceuticals Stock Trading ... (Yahoo Finance)

Denmark-based H. Lundbeck A/S on Monday agreed to acquire Longboard Pharmaceuticals, Inc (NASDAQ:LBPH) for $60.00 per share in cash.

Post cover
Image courtesy of "STAT"

Lundbeck to buy neurology-focused Longboard Pharmaceuticals in ... (STAT)

Both the Danish pharma company and the California-based biotech are focused on treating brain-related diseases.

Post cover
Image courtesy of "Business Wire"

Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic ... (Business Wire)

Longboard is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Its lead asset, ...

Top 1% Biotech Longboard Scores A $2.6 Billion Deal And ... (Investor's Business Daily)

Lundbeck announced Monday it would buy Longboard Pharmaceuticals in a $2.6 billion deal that sent Longboard stock to a record high.

Longboard Pharmaceuticals' stock soars amid Lundbeck's $2.6 ... (Morningstar.com)

The deal has a total transaction equity value of $2.6 billion and $2.5 billion net of cash. Funding will be through existing cash resources and bank financing, ...

Lundbeck to acquire Longboard Pharmaceuticals in strategic deal ... (PharmaTimes)

The acquisition includes Longboard's lead asset, bexicaserin, which is in late-stage development for DEEs such as Dravet syndrome and Lennox-Gastaut syndrome.

Lundbeck Agrees to Terms to Acquire Longboard Pharmaceuticals (Pharmaceutical Executive)

Acquisition of Longboard grants Lundbeck access to bexicaserin, 5-HT2C receptor agonist that has demonstrated promise in treating seizures associated with ...

Longboard Pharmaceuticals Announces $2.6 Billion Sale to ... (Cooley)

New York – October 14, 2024 – Cooley advised Longboard Pharmaceuticals (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing ...

Post cover
Image courtesy of "wsgr.com"

Firm Advises Evercore on Longboard Pharmaceuticals' $2.6 Billion ... (wsgr.com)

The transaction is valued at approximately $2.6 billion. Wilson Sonsini Goodrich & Rosati advised Evercore, Longboard's financial advisor, in connection with ...

Post cover
Image courtesy of "pharmaceutical-technology.com"

Lundbeck to acquire Longboard Pharmaceuticals for $2.6bn (pharmaceutical-technology.com)

Bexicaserin is currently under evaluation in a global Phase III clinical programme known as DEEp SEA. October 15, 2024.

Post cover
Image courtesy of "Contract Pharma"

Lundbeck Agrees to Acquire Longboard Pharmaceuticals (Contract Pharma)

Enhances and complements its Focused Innovator strategy and advances its goal of building a neuro-rare disease franchise.

Post cover
Image courtesy of "Medical Marketing and Media"

Lundbeck picks up Longboard Pharmaceuticals for $2.6B (Medical Marketing and Media)

Lundbeck's acquisition of Longboard Pharmaceuticals is meant to bolster its neuro-rare disease franchise, the drugmaker stated.

Post cover
Image courtesy of "Business Wire"

LONGBOARD PHARMACEUTICALS INVESTOR ALERT by the ... (Business Wire)

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed.

Explore the last week